New germline mutations in BRCA1, ATM, MUTYH, and RAD51D genes in Tuvans early-onset breast cancer patients
DOI:
https://doi.org/10.32471/exp-oncology.2312-8852.vol-43-no-1.15587Keywords:
BRCA, breast cancer, germline mutation, Mongoloid race, TuvansAbstract
Background: In Russia, more than 50,000 women are diagnosed with breast cancer (BC) every year. Russia is a multinational country — about 200 ethnic groups live on its territory. Khakass, Buryats, Tuvans and other ethnic groups show higher rate of increase in BC incidence and a younger age of first diagnosed BC compared to Caucasian ethnicities. We focused on Tuvan ethnic group to find specific genetic aberrations associated with BC. There are no BC prevention models as well as standards for the treatment of inherited BC in Tuvans. In this context, the search for genetic markers of early cancer detection and the development of criteria for therapy response are relevant. Aim: To identify hereditary mutations in BC-associated genes in Tuvan women. Materials and Methods: 24 patients with early-onset BC (range, 25 to 46 years) were enrolled in the study. Genomic DNA isolated from blood samples was used to prepare libraries using a capture-based target enrichment kit covering 27 genes (ATM, APC, BARD1, BRCA1, BRCA2, BRIP1, CDH1, CHEK2, EPCAM, FAM175A, MLH1, MRE11A, MSH2, MSH6, MUTYH, NBN, PALB2, PIK3CA, PMS2, PMS2CL, PTEN, RAD50, RAD51C, RAD51D, STK11, TP53 and XRCC2). Next-generation sequencing was performed using the Illumina NextSeq500 System. Results: In our study, one pathogenic mutation was detected in BRCA1 (rs80357868) gene (prevalence of 4%, 1/24). We identified the truncating 3875_3878delGTCT mutation of BRCA1 gene in Tuvans BC patient aged 34 years. We also detected three mutations that were probably damaging by PolyPhen2 and/or deleterious by SIFT in ATM (rs781023264), MUTYH (rs199840380) and RAD51D (rs145309168) genes. Conclusion: To the best of our knowledge, this is the first report that describes the highly pathogenic variant in the BRCA1 gene (rs80357868) and possibly damaging (PolyPhen2) germline variants in the ATM (rs781023264), MUTYH (rs199840380) and RAD51D (rs145309168) genes in young Tuvans BC patient.
References
Zhuikova LD, Choynzonov EL, Ananina OA. Cancer incidence in Siberia and Russian Far East. Siberian J Oncol 2019; 18: 5–11 (in Russian).
Sokolenko AP, Preobrazhenskaya EV, Aleksakhina SN, et al. Candidate gene analysis of BRCA1/2 mutation-negative high-risk Russian breast cancer patients. Cancer Lett 2015; 359: 259–61.
Cherdyntseva NV, Pisareva LF, Panferova YV, et al. Ethnic aspects of hereditary breast cancer in the region of Siberia. Vestnik Ros Akad Med Nauk 2014; 69: 72–9 (in Russian).
Butler JM. DNA Extraction Methods. In: Advanced Topics in Forensic DNA Typing: Methodology. Academic Press, 2012. p. 29–47.
McKenna A, Hanna M, Banks E, et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res 2010; 20: 1297–303.
DePristo MA, Banks E, Poplin R, et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat Genet 2011; 43: 491–8.
Van der Auwera GA, Carneiro MO, Hartl C, et al. From FastQ data to high confidence variant calls: the Genome Analysis Toolkit best practices pipeline. Curr Protoc Bioinformatics 2013; 43: 11.10.1–33.
Chen Z, Zhang Y, Fan A, et al. Brief communication: Y-chromosome haplogroup analysis indicates that Chinese Tuvans share distinctive affinity with Siberian Tuvans. Am J Phys Anthropol 2011; 144: 492–7.
Kiseleva OA, Robustova OV, Bessmertny AM, et al. Prevalence of primary glaucoma in representatives of different races and ethnic groups in Russia and in CIS. Oftalmologia 2013; 10: 11–5 (In Russian).
Nakamura S, Kwong A, Kim SW, et al. Current status of the management of hereditary breast and ovarian cancer in Asia: First report by the Asian BRCA Consortium. Public Health Genomics 2016; 19: 53–60.
Bhaskaran SP, Chandratre K, Gupta H. Germline variation in BRCA1/2 is highly ethnic-specific: Evidence from over 30,000 Chinese hereditary breast and ovarian cancer patients. Int J Cancer 2019; 145: 962–73.
Gaj P, Kluska A, Nowakowska D, et al. High frequency of BRCA1 founder mutations in Polish women with nonfamilial breast cancer. Fam Cancer 2012; 11: 623–8.
Deng S, Wang Y, Ke Y, et al. Analysis of the mutations of BRCA1 in 9 familiar breast cancer patients. Beijing Da Xue Xue Bao Yi Xue Ban 2003; 35: 373–6 (in Chinese).
Kim H, Cho DY, Choi DH, et al. Characteristics and spectrum of BRCA1 and BRCA2 mutations in 3,922 Korean patients with breast and ovarian cancer. Breast Cancer Res Treat 2012; 134: 1315–26.
Liu X, Li H, Shao B, et al. Identification of recurrent BRCA1 mutation and its clinical relevance in Chinese triple-negative breast cancer cohort. Cancer Med 2017; 6: 547–54.
Lek M, Karczewski KJ, Minikel EV, et al. Exome Aggregation Consortium. Analysis of protein-coding genetic variation in 60,706 humans. Nature 2016; 536: 285–91.
Wickramanayake A, Bernier G, Pennil C, et al. Loss of function germline mutations in RAD51D in women with ovarian carcinoma. Gynecol Oncol 2012; 127: 552–5.
Lin PH, Kuo WH, Huang AC, et al. Multiple gene sequencing for risk assessment in patients with early-onset or familial breast cancer. Oncotarget 2016; 7: 8310–20.
Ellis D, Greenman J, Hodgson S, et al. Low prevalence of germline BRCA1 mutations in early onset breast cancer without a family history. J Med Genet 2000; 37: 792–4.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Experimental Oncology
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
